<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font6" size="10" family="Giovanni-BookItalic,Italic" color="#000000"/>
<text top="41" left="55" width="118" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title"><i>Clinical and Molecular Allergy</i></text>
<text top="41" left="173" width="28" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="0" tag_type="title"> 2007, </text>
<text top="41" left="200" width="5" height="10" font="font2" id="p1_t3" reading_order_no="2" segment_no="0" tag_type="title"><b>5</b></text>
<text top="41" left="205" width="7" height="10" font="font1" id="p1_t4" reading_order_no="3" segment_no="0" tag_type="title">:2</text>
<text top="41" left="343" width="211" height="10" font="font1" id="p1_t5" reading_order_no="4" segment_no="1" tag_type="text">http://www.clinicalmolecularallergy.com/content/5/1/2</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t6" reading_order_no="109" segment_no="15" tag_type="text">Page 2 of 6</text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t7" reading_order_no="110" segment_no="16" tag_type="text"><i>(page number not for citation purposes)</i></text>
<text top="87" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="5" segment_no="2" tag_type="text">tive potential, particularly in case of polyclonal</text>
<text top="98" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="6" segment_no="2" tag_type="text">antibodies, is more reliably assessed by inhibition tests</text>
<text top="110" left="55" width="117" height="9" font="font4" id="p1_t10" reading_order_no="7" segment_no="2" tag_type="text">than by direct binding tests.</text>
<text top="134" left="55" width="165" height="10" font="font5" id="p1_t11" reading_order_no="8" segment_no="4" tag_type="title"><b>Cross-reactivity and allergenicity</b></text>
<text top="145" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="9" segment_no="5" tag_type="text">For various reasons, often related to regulatory safety</text>
<text top="157" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="10" segment_no="5" tag_type="text">issues, a discussion is ongoing on prediction of allergenic-</text>
<text top="169" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="11" segment_no="5" tag_type="text">ity. This involves both prediction of de novo allergenicity</text>
<text top="181" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="5" tag_type="text">as well as prediction of cross-reactivity. The latter, predic-</text>
<text top="192" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="13" segment_no="5" tag_type="text">tion of allergen cross-reactivity, is the topic of this com-</text>
<text top="204" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="14" segment_no="5" tag_type="text">munication, with emphasis on quantitative and</text>
<text top="216" left="55" width="101" height="9" font="font4" id="p1_t18" reading_order_no="15" segment_no="5" tag_type="text">methodological aspects.</text>
<text top="239" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="16" segment_no="6" tag_type="text">Clinically, allergic cross-reactivity is often encountered as</text>
<text top="251" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="17" segment_no="6" tag_type="text">symptoms without prior exposure. Another common clin-</text>
<text top="263" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="18" segment_no="6" tag_type="text">ical situation is the occurrence of symptoms upon expo-</text>
<text top="275" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="19" segment_no="6" tag_type="text">sure to allergenic sources that are unlikely to sensitise,</text>
<text top="286" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="20" segment_no="6" tag_type="text">such as apples. In Northern Europe it is rare to find apple</text>
<text top="298" left="55" width="241" height="9" font="font4" id="p1_t24" reading_order_no="21" segment_no="6" tag_type="text">allergy in the absence of birch allergy. The major birch</text>
<text top="310" left="55" width="241" height="9" font="font4" id="p1_t25" reading_order_no="22" segment_no="6" tag_type="text">pollen allergen acts as the sensitizer or primary allergen,</text>
<text top="322" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="23" segment_no="6" tag_type="text">which by definition is able to trigger the immune system</text>
<text top="333" left="55" width="241" height="9" font="font4" id="p1_t27" reading_order_no="24" segment_no="6" tag_type="text">to produce IgE antibodies. The homologous protein in</text>
<text top="345" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="25" segment_no="6" tag_type="text">apple Mal d 1 is an incomplete allergen, because it is una-</text>
<text top="357" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="6" tag_type="text">ble (or: extremely inefficient) to induce IgE antibodies,</text>
<text top="369" left="55" width="241" height="9" font="font4" id="p1_t30" reading_order_no="27" segment_no="6" tag_type="text">but is able to elicit symptoms due to its ability to trigger</text>
<text top="380" left="55" width="163" height="9" font="font4" id="p1_t31" reading_order_no="28" segment_no="6" tag_type="text">mast cells loaded with IgE anti-Bet v 1.</text>
<text top="404" left="55" width="241" height="9" font="font4" id="p1_t32" reading_order_no="29" segment_no="10" tag_type="text">Cross-reactivity is sometimes seen as a property of a sub-</text>
<text top="416" left="55" width="241" height="9" font="font4" id="p1_t33" reading_order_no="30" segment_no="10" tag_type="text">group of antibodies: antibodies to some epitopes (recur-</text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t34" reading_order_no="31" segment_no="10" tag_type="text">ring epitopes such as cross-reactive carbohydrate</text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t35" reading_order_no="32" segment_no="10" tag_type="text">determinants (CCD<a href="">s [2]) are m</a>ore likely to be cross-reac-</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t36" reading_order_no="33" segment_no="10" tag_type="text">tive than antibodies to other epitopes. However, it is often</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="10" tag_type="text">more appropriate to use cross-reactivity to describe a rela-</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t38" reading_order_no="35" segment_no="10" tag_type="text">tion between two allergens (which I will refer to as Ag1</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t39" reading_order_no="36" segment_no="10" tag_type="text">and Ag2; alternatively, I will use the birch allergen Bet v 1</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="10" tag_type="text">and the cross-reactive apple allergen Mal d 1 as examples):</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="10" tag_type="text">the closer the similarity between two allergens, the more</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="10" tag_type="text">likely it is to find a cross-reactive antibody. In either case,</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t43" reading_order_no="40" segment_no="10" tag_type="text">the concept of cross-reactivity concerns (at least) three</text>
<text top="545" left="55" width="241" height="9" font="font4" id="p1_t44" reading_order_no="41" segment_no="10" tag_type="text">rather than two reagents: two allergens and an antibody.</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t45" reading_order_no="42" segment_no="10" tag_type="text">Since it is impossible to test all antibodies, we have to live</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="10" tag_type="text">with the frustrating thought that it is impossible to prove</text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t47" reading_order_no="44" segment_no="10" tag_type="text">that two allergens completely lack cross-reactivity. Con-</text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t48" reading_order_no="45" segment_no="10" tag_type="text">versely, it is also impossible to prove that they are fully</text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="10" tag_type="text">cross-reactive. It is all a matter of probability, which in</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t50" reading_order_no="47" segment_no="10" tag_type="text">many cases is either very close to 0 or very close to 1. In</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t51" reading_order_no="48" segment_no="10" tag_type="text">many other cases it is, however, easy to demonstrate some</text>
<text top="639" left="55" width="64" height="9" font="font4" id="p1_t52" reading_order_no="49" segment_no="10" tag_type="text">cross-reactivity.</text>
<text top="663" left="55" width="229" height="10" font="font5" id="p1_t53" reading_order_no="50" segment_no="13" tag_type="title"><b>Prediction of cross-reactivity from the amino </b></text>
<text top="674" left="55" width="70" height="10" font="font5" id="p1_t54" reading_order_no="51" segment_no="13" tag_type="title"><b>acid sequence</b></text>
<text top="686" left="55" width="241" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="14" tag_type="text">Antibodies largely bind to surface patches of folded pro-</text>
<text top="698" left="55" width="241" height="9" font="font4" id="p1_t56" reading_order_no="53" segment_no="14" tag_type="text">teins (epitopes), so knowledge of the full 3D structures of</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t57" reading_order_no="54" segment_no="14" tag_type="text">the target protein and the related allergens would clearly</text>
<text top="721" left="55" width="241" height="9" font="font4" id="p1_t58" reading_order_no="55" segment_no="14" tag_type="text">be an advantage for such a prediction and now more com-</text>
<text top="87" left="313" width="241" height="9" font="font4" id="p1_t59" reading_order_no="56" segment_no="3" tag_type="text">monly available (or the 3D structures can be reliably pre-</text>
<text top="98" left="313" width="241" height="9" font="font4" id="p1_t60" reading_order_no="57" segment_no="3" tag_type="text">dicted). Undoubtedly, cross-reactivity prediction</text>
<text top="110" left="313" width="241" height="9" font="font4" id="p1_t61" reading_order_no="58" segment_no="3" tag_type="text">algorithms will be developed in which such information</text>
<text top="122" left="313" width="241" height="9" font="font4" id="p1_t62" reading_order_no="59" segment_no="3" tag_type="text">is incorporated. However, sufficiently reliable informa-</text>
<text top="134" left="313" width="241" height="9" font="font4" id="p1_t63" reading_order_no="60" segment_no="3" tag_type="text">tion on the relevant 3D structures is often not available</text>
<text top="145" left="313" width="241" height="9" font="font4" id="p1_t64" reading_order_no="61" segment_no="3" tag_type="text">and the prediction has to be based on the linear amino</text>
<text top="157" left="313" width="241" height="9" font="font4" id="p1_t65" reading_order_no="62" segment_no="3" tag_type="text">acid sequence. One of the points of debate is whether</text>
<text top="169" left="313" width="241" height="9" font="font4" id="p1_t66" reading_order_no="63" segment_no="3" tag_type="text">short stretches of 6â€“8 fully identical amino acids are reli-</text>
<text top="181" left="313" width="241" height="9" font="font4" id="p1_t67" reading_order_no="64" segment_no="3" tag_type="text">able predictors and should be used in combination with</text>
<text top="192" left="313" width="241" height="9" font="font4" id="p1_t68" reading_order_no="65" segment_no="3" tag_type="text">partial amino acid identity of longer stretches (typically</text>
<text top="204" left="313" width="241" height="9" font="font4" id="p1_t69" reading_order_no="66" segment_no="3" tag_type="text">more than 35% identity between stretches of 80 amino</text>
<text top="216" left="313" width="42" height="9" font="font4" id="p1_t70" reading_order_no="67" segment_no="3" tag_type="text"><a href="">acids [3]).</a></text>
<text top="239" left="313" width="241" height="9" font="font4" id="p1_t71" reading_order_no="68" segment_no="7" tag_type="text">Other issues related to prediction of cross-reactivity, such</text>
<text top="251" left="313" width="241" height="9" font="font4" id="p1_t72" reading_order_no="69" segment_no="7" tag_type="text">as the repertoire-modifying effect of a human homologue,</text>
<text top="263" left="313" width="241" height="9" font="font4" id="p1_t73" reading_order_no="70" segment_no="7" tag_type="text">the contribution of post-translational modification (par-</text>
<text top="275" left="313" width="241" height="9" font="font4" id="p1_t74" reading_order_no="71" segment_no="7" tag_type="text">ticularly non-mammalian glycosylation patterns), the</text>
<text top="286" left="313" width="241" height="9" font="font4" id="p1_t75" reading_order_no="72" segment_no="7" tag_type="text">possibilities and limitations of peptides as epitope mimics</text>
<text top="298" left="313" width="241" height="9" font="font4" id="p1_t76" reading_order_no="73" segment_no="7" tag_type="text">and the intriguing question whether IgE antibodies tend</text>
<text top="310" left="313" width="241" height="9" font="font4" id="p1_t77" reading_order_no="74" segment_no="7" tag_type="text">to be more cross-reactive than IgG antibodies, with its</text>
<text top="322" left="313" width="241" height="9" font="font4" id="p1_t78" reading_order_no="75" segment_no="7" tag_type="text">possible link with positive and negative regulation of B</text>
<text top="333" left="313" width="241" height="9" font="font4" id="p1_t79" reading_order_no="76" segment_no="7" tag_type="text">cells by IgE versus IgG antibodies, have been discussed</text>
<text top="345" left="313" width="67" height="9" font="font4" id="p1_t80" reading_order_no="77" segment_no="7" tag_type="text">elsewh<a href="">ere [4-6].</a></text>
<text top="369" left="313" width="233" height="10" font="font5" id="p1_t81" reading_order_no="78" segment_no="8" tag_type="title"><b>Symmetric versus asymmetric cross-reactivity</b></text>
<text top="380" left="313" width="241" height="9" font="font4" id="p1_t82" reading_order_no="79" segment_no="9" tag_type="text">Some situations of allergen cross-reactivity are almost triv-</text>
<text top="392" left="313" width="241" height="9" font="font4" id="p1_t83" reading_order_no="80" segment_no="9" tag_type="text">ial, such as the cross-reactivity between major allergens of</text>
<text top="404" left="313" width="241" height="9" font="font4" id="p1_t84" reading_order_no="81" segment_no="9" tag_type="text">botanically-related grasse<a href="">s [7</a>] and between major dust</text>
<text top="416" left="313" width="241" height="9" font="font4" id="p1_t85" reading_order_no="82" segment_no="9" tag_type="text">mite allergens. Without information on allergen exposure</text>
<text top="427" left="313" width="241" height="9" font="font4" id="p1_t86" reading_order_no="83" segment_no="9" tag_type="text">it is then virtually impossible to decide which allergen is</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t87" reading_order_no="84" segment_no="9" tag_type="text">the sensitizer. Symmetric cross-reactivity a likely possibil-</text>
<text top="451" left="313" width="241" height="9" font="font4" id="p1_t88" reading_order_no="85" segment_no="9" tag_type="text">ity: both allergens in the couple can sensitize and both can</text>
<text top="463" left="313" width="241" height="9" font="font4" id="p1_t89" reading_order_no="86" segment_no="9" tag_type="text">largely (but not completely) inhibit the binding of IgE to</text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t90" reading_order_no="87" segment_no="9" tag_type="text"><a href="">the other allergen (figure 1A). </a>In the birch/apple situation</text>
<text top="486" left="313" width="241" height="9" font="font4" id="p1_t91" reading_order_no="88" segment_no="9" tag_type="text">the situation is different (at least in Northern Europe) [<a href="">8</a>].</text>
<text top="498" left="313" width="241" height="9" font="font4" id="p1_t92" reading_order_no="89" segment_no="9" tag_type="text">Cross-reactivity is asymmetric (figure <a href="">1B), as can</a> be dem-</text>
<text top="510" left="313" width="241" height="9" font="font4" id="p1_t93" reading_order_no="90" segment_no="9" tag_type="text">onstrated in vitro by reciprocal IgE antibody neutraliza-</text>
<text top="521" left="313" width="241" height="9" font="font4" id="p1_t94" reading_order_no="91" segment_no="9" tag_type="text">tion. The usual finding is that birch allergen inhibits IgE</text>
<text top="533" left="313" width="241" height="9" font="font4" id="p1_t95" reading_order_no="92" segment_no="9" tag_type="text">binding to the apple allergen similar to or even better than</text>
<text top="545" left="313" width="241" height="9" font="font4" id="p1_t96" reading_order_no="93" segment_no="9" tag_type="text">the inhibition found by using equimolar amounts of the</text>
<text top="557" left="313" width="241" height="9" font="font4" id="p1_t97" reading_order_no="94" segment_no="9" tag_type="text">apple allergen as inhibitor, whereas the apple allergen</text>
<text top="568" left="313" width="233" height="9" font="font4" id="p1_t98" reading_order_no="95" segment_no="9" tag_type="text">only partially inhibits IgE binding to the birch allergen.</text>
<text top="592" left="313" width="222" height="10" font="font5" id="p1_t99" reading_order_no="96" segment_no="11" tag_type="title"><b>Issues on the quantification of the degree of </b></text>
<text top="604" left="313" width="159" height="10" font="font5" id="p1_t100" reading_order_no="97" segment_no="11" tag_type="title"><b>cross-reactivity of two allergens</b></text>
<text top="615" left="313" width="241" height="9" font="font4" id="p1_t101" reading_order_no="98" segment_no="12" tag_type="text">First, a semantic issue: polyclonal versus monoclonal</text>
<text top="627" left="313" width="241" height="9" font="font4" id="p1_t102" reading_order_no="99" segment_no="12" tag_type="text">cross-reactivity. The word "cross-reactivity" is used differ-</text>
<text top="639" left="313" width="241" height="9" font="font4" id="p1_t103" reading_order_no="100" segment_no="12" tag_type="text">ently in the polyclonal situation and the monoclonal sit-</text>
<text top="651" left="313" width="203" height="9" font="font4" id="p1_t104" reading_order_no="101" segment_no="12" tag_type="text">uation. Traditionally, it is used to describe the </text>
<text top="651" left="516" width="38" height="9" font="font6" id="p1_t105" reading_order_no="102" segment_no="12" tag_type="text"><i>polyclonal</i></text>
<text top="662" left="313" width="241" height="9" font="font4" id="p1_t106" reading_order_no="103" segment_no="12" tag_type="text">situation as encountered in the body. Many different anti-</text>
<text top="674" left="313" width="241" height="9" font="font4" id="p1_t107" reading_order_no="104" segment_no="12" tag_type="text">bodies recognize Ag1 (for example: Bet v 1). Some of these</text>
<text top="686" left="313" width="241" height="9" font="font4" id="p1_t108" reading_order_no="105" segment_no="12" tag_type="text">antibodies react with Ag2 (Mal d 1). The degree of cross-</text>
<text top="698" left="313" width="241" height="9" font="font4" id="p1_t109" reading_order_no="106" segment_no="12" tag_type="text">reactivity can be expressed as the fraction of anti-Bet v 1</text>
<text top="709" left="313" width="241" height="9" font="font4" id="p1_t110" reading_order_no="107" segment_no="12" tag_type="text">antibodies that react with Mal d 1. This fraction will vary</text>
<text top="721" left="313" width="241" height="9" font="font4" id="p1_t111" reading_order_no="108" segment_no="12" tag_type="text">between individuals and usually varies within one indi-</text>
</page>
</pdf2xml>
